FDA approves Vertex's non-opioid painkiller, first new kind of pain medicine in decades
The Vertex drug is a milestone after a long history of unsuccessful efforts to develop painkillers without the addictive ...
Time on MSN10d
FDA Approves the First Non-Opioid Pain Drug in 20 Years
The prescription pills, sold under the brand name Journavx and made by Vertex Pharmaceuticals, are taken twice a day and ...
Arizona Daily Star13d
FDA approves new painkiller that shows promise and challenges of opioid alternatives
It's the first new pharmaceutical approach to treating pain in over 20 years, designed to eliminate risks of addiction and ...
pharmaphorum2d
Vertex buys diabetes cell therapy rival ViaCyte for $320m
Vertex' therapy takes the form of stem cell-derived human pancreatic islet cells, which secrete insulin in the body in response to rising blood glucose. The aim is to replace the pancreatic tissue ...
Discover Magazine13d
FDA Approves Opioid Alternative for Pain Relief That Is Non-Addictive
Because the drug doesn’t target the brain, it has less potential for addiction. Learn why this could help the opioid crisis.
The Tribune-Democrat14d
FDA approves painkiller designed to eliminate the risk of addiction associated with opioids
Federal officials on Thursday approved a new type of pain pill designed to eliminate the risks of addiction and overdose ...
WPBF14d
FDA approves new pain drug Journavx as opioid alternative
The U.S. Food and Drug Administration said it approved Vertex Pharmaceuticals' Journavx ... receive nerve signals from different parts of the body. Those chemical interactions also give rise ...
Morningstar14d
Vertex Announces CASGEVY® Reimbursement Agreement for the Treatment of Sickle Cell Disease in England
Vertex also has a robust clinical pipeline of investigational therapies across a range of modalities in other serious diseases where it has deep insight into causal human biology, including ...
pharmaphorum2d
FDA fast tracks type 1 diabetes cell therapy from Vertex
Vertex Pharma has made its name ... The therapy takes the form of stem cell-derived human pancreatic islet cells, which secrete insulin in the body in response to rising blood glucose.
AFP14d
Vertex Announces CASGEVY® Reimbursement Agreement for the Treatment of Sickle Cell Disease in England
Vertex Pharmaceuticals (Nasdaq: VRTX) announced today a reimbursement agreement with NHS England for eligible sickle cell disease (SCD) patients to access the CRISPR/Cas9 gene-edited therapy, CASGEVY® ...